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Hookworm disease, characterized by severe anemia and cognitive and growth delays, currently affects an
estimated 740 million people worldwide. Despite the prevalence of this parasitic disease, few effective
drug therapies are in use today, and the heavy reliance upon benzimidazoles highlights the need for
the development of novel chemotherapies. Recent work with the trematode parasite Schistosoma mansoni
has identiﬁed oxadiazole 2-oxides as effective antischistosomal compounds that function by targeting
and inhibiting the antioxidant enzyme, thioredoxin glutathione reductase. In this study, a related
enzyme, glutathione reductase, from the human hookworm Ancylostoma ceylanicum was identiﬁed and
characterized, and its in vitro activity in the presence of the oxadiazole 2-oxides was analyzed. Ex vivo
worm killing assays were also conducted to establish the relationship between a given compound’s effect
upon worm survival and inhibition of recombinant glutathione reductase (rAceGR). Finally, the in vivo
anthelminthic efﬁcacy of furoxan (Fx) was assessed in the hamster model of hookworm infection. The
predicted amino acid sequence of AceGR contained a prototypical glutathione reductase active site
sequence, but no thioredoxin reductase consensus sequences, suggesting that the glutathione and thio-
redoxin pathways of A. ceylanicum are distinct. Although 10 of the 42 oxadiazole 2-oxides tested inhibited
rAceGR activity by at least 50%, and 15 compounds were toxic to parasites ex vivo, little overlap existed
between these two results. We therefore suggest that AceGR is not the primary target of the oxadiazole 2-
oxides in effecting parasite death. Lastly, oral treatment of A. ceylanicum infected hamsters with furoxan
resulted in signiﬁcantly improved weight gains and reduced intestinal worm burdens compared to vehi-
cle treated controls, supporting continued development of this molecule as a novel anthelminthic.
 2012 Australian Society for Parasitology Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction developing, rural areas of sub-Saharan Africa, South–East Asia,Along with malaria, schistosomiasis, and leishmaniasis, hook-
worm disease is a parasitic disease targeted by the World Health
Organization’s Initiative for Vaccine Research as one of the major
public health challenges facing international healthcare (WHO,
2006). Caused by hematophagous parasitic nematodes that attach
to and feed on the intestinal mucosa, hookworm infection is char-
acterized by severe anemia, malnutrition, and intrauterine as well
as childhood growth delay (Hotez et al., 2005). Prevalent in thePublished by Elsevier Ltd.
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Open accand Latin America, up to 740 million people worldwide are cur-
rently infected with hookworms, and treatment of this infection
is therefore relevant to the advancement of child, adult, and repro-
ductive health (Hotez et al., 2010). Hookworm infection occurs
with high frequency in both children and adults in endemic areas,
and although anthelminthic treatment programs have been initi-
ated, concern for acquired drug resistance, the unlikely sustainabil-
ity of perpetual deworming campaigns and the prevalence of
reinfection strongly supports the development of novel chemo-
therapies (Bethony et al., 2006; Keiser and Utzinger, 2010; Bungiro
and Cappello, 2011). Development of such strategies requires iden-
tiﬁcation of drug targets essential for parasite survival, and hook-
worm enzymes involved in bloodmeal metabolism are therefore
attractive in this regard.
In addition to providing essential nutrients, bloodfeeding also
exposes hookworms to potentially toxic iron-containing com-
pounds that promote the generation of reactive oxidative speciesess under CC BY-NC-ND license.
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molecular damage can occur (Henkle-Dührsen and Kampkötter,
2001). Thus, hematophagous parasites, including hookworms, have
evolved efﬁcient mechanisms for detoxifying the ROS that are gen-
erated through such processes as the hemolysis of red blood cells
and protease-mediated digestion of hemoglobin (Selkirk et al.,
1998). Most organisms possess two antioxidant pathways—the thi-
oredoxin (Trx) system and the glutathione (GSH) system—that
mediate the conversion of ROS via an electron transfer cascade,
which sequentially reduces and oxidizes the key components of
the pathways, ultimately transferring electrons to downstream tar-
gets (Salinas et al., 2004). Recent work has identiﬁed oxadiazole 2-
oxides, nitric oxide-donating compounds, as lead compounds that
target thioredoxin glutathione reductase (TGR), a multifunctional
redox protein that bridges the GSH and Trx pathways in trema-
todes (Alger and Williams, 2002; Sayed et al., 2008). The presence
of oxadiazole 2-oxides, which are analogs of the parent compound
furoxan, is intimately linked to the inhibition of TGR and worm
killing in vitro and in vivo, suggesting their efﬁcacy as novel ant-
helminthics (Rai et al., 2009). Preliminary studies have revealed
that oxadiazole 2-oxides effectively inhibit the survival of adult
Ancylostoma ceylanicum hookworms in ex vivo culture as well as
in an in vivo model of hookworm disease. However, preliminary
data support the hypothesis that hookworms do not express the
multifunctional gene product TGR, instead relying on distinct
enzymatic pathways for thioredoxin and glutathione reductase
activities (Vermeire, unpublished data). Therefore, the mechanism
by which oxadiazoles kill A. ceylanicum remains unknown.
Among the enzymes of the GSH pathway, glutathione reductase
(GR) provides reducing equivalents to downstream pathway mem-
bers and is consequently fundamental to the functioning of the
system (Otero et al., 2010). We therefore hypothesized that A. cey-
lanicum possesses the antioxidant enzyme glutathione reductase
(GR) and that it is structurally and functionally distinct from a thi-
oredoxin reductase (or pathway) counterpart. We further hypoth-
esized that hookworm GR serves as the target for and is inhibited
by oxadiazole 2-oxides. In this report we identify and characterize
a glutathione reductase enzyme from A. ceylanicum (AceGR), the
reaction kinetics of the puriﬁed recombinant protein and its behav-
ior in enzyme activity assays containing furoxan and structurally
related analogs in vitro. We also report on the nematicidal activity
of these compounds in ex vivo experiments as well as in an in vivo
model of hookworm disease. By determining whether AceGR
serves as the target for these compounds, it will be possible to fur-
ther our understanding of the mechanism by which hookworms
protect themselves from oxidative damage and to advance towards
the development of new anthelminthic chemotherapies targeting
these mechanisms.2. Experimental procedures
2.1. Identiﬁcation of A. ceylanicum glutathione reductase
To identify the A. ceylanicum GR cDNA, the GenBank hookworm
expressed sequence tag (EST) database was queried using a proto-
typical Caenorhabditis elegans glutathione reductase amino acid se-
quence (GenBank ID: CAD88214) and the tBLASTn algorithm.
Twenty-two A. ceylanicum EST sequences with homology (E-values
of 61  105) to the prototype C. elegans sequence were assembled
into a contig using Vector NTI ContigExpress software (Invitrogen).
The sequence obtained was used to create the following gene spe-
ciﬁc oligonucleotide primers: forward 50-ATGGCTACCGTACGTGAA-
30 and reverse 50-GTACTGTGGCCGCTCGCCTCC-30. A full-length
cDNA was then ampliﬁed by the polymerase chain reaction (PCR)
from adult A. ceylanicum cDNA created from total RNA isolatedfrom adult male and female worms. PCR products were separated
by electrophoresis, gel puriﬁed (Qiagen), ligated into pCR 2.1
(Invitrogen) and sequenced at the Yale W.M. Keck facility. The se-
quence was deposited into GenBank (GenBank ID: JQ086360).
2.1.1. Complimentary DNA (cDNA) synthesis
First strand cDNA was synthesized from hookworm total RNA
for use in PCR reactions. RNA was extracted directly from parasites
using the TRIzol (Invitrogen, Carlsbad, CA) reagent according to
the manufacturer’s instructions and the resulting RNA pellet was
resuspended in diethypyrocarbonate (DEPC)-treated water. A
15 lL reaction containing 2 lg of total RNA with 1 lL of 500 lg/
mL random hexamers (Promega, Madison, WI) and 1 lL of
500 lg/mL oligo(dT) (Promega) primers was heated to 65 C for
15 min and was cooled to 4 C for 10 min before proceeding. The
reaction contents were then brought up to a 30 lL reaction volume
containing 100U of MMLV-RT (Promega) followed by reverse-tran-
scription into cDNA at 42 C for 2 h and ﬁnally incubation for
15 min at 70 C to inactivate the MMLV-RT enzyme.
2.2. PCR cloning, expression, and puriﬁcation of recombinant AceGR
To obtain recombinant AceGR (rAceGR) the complete open read-
ing frame (ORF) of an A. ceylanicum GR was ampliﬁed by PCR using
gene-speciﬁc oligonucleotide primers (see above) and ligated into
the pTrcHis2 TOPO cloning vector (Invitrogen). BL21(DE3) cells con-
taining AceGR in pTricHis2 were grown on 50 lg/mL ampicillin LB
plates spread with 20 lL of a 2 mM glucose solution. Selected colo-
nies were cultured in LBmedium supplementedwith 10 lL/mL car-
benicillin and 0.5% glucose. Plasmids were isolated (Qiagen) and
correct insert directionality was veriﬁed using restriction digest
and DNA sequencing (Yale W.M. Keck). The production of recombi-
nant protein was induced with 1 mM isopropyl b-D-1 thiolgalacto-
pyranoside (IPTG, American Bioanalytical). Pelleted cells were
resuspended in binding buffer (20 mMsodiumphosphate, 0.5 M so-
diumchloride, 5 mM imidazole, pH 7.4) and sonicated at 30% output
3 times for 2 min. Following centrifugation, the ﬁltered supernatant
was puriﬁed over a 1 mL nickel afﬁnity chromatography column
(Amersham, GE Healthcare, 17-0480-01). The histidine-tagged pro-
tein was eluted from the column with imidazole buffer (20 mM so-
dium phosphate, 0.5 M sodium chloride, 500 mM imidazole pH 7.4)
and dialyzed against phosphate-buffered saline (PBS; Invitrogen).
Protein purity and concentration were veriﬁed by SDS–PAGE,
immunoblotting, and a BCA™ (bicinchoninic acid) protein assay
(Pierce). The recombinant form of AceGR was identiﬁed by immu-
noblotting using a a-6 histidine antibody conjugated to horserad-
ish peroxidase (Sigma). The blotwas incubated overnight at 4 C in a
5% nonfat milk/PBS/0.1% Tween solution with 1:5000 antibody. Sig-
nal was detected with the addition of 1.5 mL of SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientiﬁc).
2.3. rAceGR kinetic assays
Assays were performed in UV-Star 96-well plates (Greiner Bio-
One, 655801) in a Molecular Devices Spectramax 190 kinetic plate
reader at 24 C. The 50,50-dithiobis(2-nitrobenzoic acid) (DTNB) as-
say was used to determine activity of rAceGR (Kuntz et al., 2007).
This reaction couples the oxidation of NADPH to the reduction of
GSSG and then of DTNB, producing 2 equivalents of 50-thionitro-
benzoic acid dianion (TNB2) that possess a molar absorptivity of
14.15 mM1 cm1. Speciﬁc activity (S.A.) was calculated in Units/
mg using:
S:A: ¼
DA412
min
 
ðV reactionÞ
ð2 14:15 mMmin1ÞðVenzymeÞð½ProteinmgmL1Þ
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fer (100 mM potassium phosphate, pH 7.5, with 1 mM EDTA) (Sig-
ma). The initial increase in absorption at 412 nm was recorded for
3 min immediately following the addition of a master mix contain-
ing DTNB (TCI America) and GSSG (MP Biomedicals). Enzyme
kinetics with NADPH were investigated by combining the recombi-
nant enzyme (5 nM ﬁnal concentration) and varying concentra-
tions of NADPH (from 0 to 2 mM) (Sigma) in assay buffer,
followed by the addition of 750 lMDTNB and 1 mM GSSG. Enzyme
kinetics with GSSG were determined by combining 5 nM rAceGR
with 250 lM NADPH in assay buffer, followed by the addition of
750 lM DTNB and varying concentrations (from 0 to 4 mM) of
GSSG. All assays were run in triplicate and a negative control con-
taining no NADPH was used. Kinetic parameters were obtained by
plotting initial velocity against substrate concentration and then
using Michaelis–Menten least squares kinetic analysis and Linewe-
aver–Burk plots on Graph Pad Prism software (Graph Pad Software,
http://www.graphpad.com).2.4. Enzyme inhibitor screening
Furoxan and structural analogs of furoxan were synthesized at
the NIH Chemical Genomics as part of the Therapeutics for Rare
and Neglected Diseases (TRND) program (Rai et al., 2009). A com-
plete list of all compounds tested and their structures is available
in Supplementary data (pending availability, it is the policy of
the NIH Center for Advancing Translational Sciences that all ana-
logues are obtainable via direct request to the authors). Com-
pounds were dissolved in dimethyl sulfoxide (DMSO) (Fisher) as
10 mM stock solutions. Assays were performed as 200 lL reactions
by ﬁrst incubating 5 nM rAceGR with NADPH (250 lM) and either
furoxan ([ﬁnal] = 50 lM), analog compounds ([ﬁnal] = 50 lM), or
equivalent volume of DMSO for 15 min in GR assay buffer at RT.
The kinetic reaction was followed for 3 min by measuring the OD
at 412 nm immediately following the addition of a master mix of
GSSG (1 mM) and DTNB (750 lM). All assays were run in triplicate,
and mean values for each triplicate were used. The percent change
in optical density reading over the ﬁrst 60 s for each inhibitor was
compared against that for the DMSO control. Compounds exhibit-
ing >50% inhibition (as compared to the DMSO control) after 30 s
were further investigated by varying inhibitor concentration from
0 nM to 50 lM to determine an IC50 value. Percent inhibition of the
DMSO control reaction was graphed against increasing log[inhibi-
tor] and a dose–response curve analysis was completed using
Graph Pad Prism.2.5. Ex vivo worm survival assays
Following removal from the small intestine of their hamster
hosts, adult A. ceylanicum were washed with hookworm culture
medium (HCM) composed of RPMI medium (Cellgro) containing
50 mg/mL streptomycin (Fisher BioReagents), 100 units/mL peni-
cillin G (Sigma), and 10 lg/mL Fungizone (Invitrogen) (Cappello
et al., 2006). Adult male and female worms were placed in 15 mL
conical tubes containing 10 mL of HCM and cultured in a 5% CO2
incubator at 37 C overnight. Worms were distributed to the wells
of a 24-well plate containing 1 mL of fresh HCM, and for each
experiment 10–20 male and female worms were placed in individ-
ual wells. Each inhibitor compound was tested in triplicate. Test
compounds were dissolved in DMSO and added at 100 lM ﬁnal
concentration. Parasite motility and morphology were observed
under a dissecting microscope at 12 h intervals for 120 h following
treatment. Parasites were considered dead once they lost motility
completely. Control reactions were simultaneously performed
using equivalent volumes of DMSO alone.2.6. In vivo treatment with oxadiazole 2-oxides
Groups of hamsters (n = 4) were infected with 75 third stage A.
ceylanicum larvae by oral gavage and followed for 20 days post
infection (DPI) to monitor blood hemoglobin levels and weight
gain (Bungiro et al., 2001; Cappello et al., 2006). Treatment regi-
mens (commencing 12 DPI) targeted adult worms with furoxan
(50 mg/kg, 200 lL, formulated in 10% DMSO: 40% propylene car-
bonate: 50% saline, q.d. orally for 3 days). Albendazole (ABZ;
10 mg/kg, 200 lL in water) was given once orally as indicated in
the relevant ﬁgure legends. A control group of A. ceylanicum in-
fected hamsters received 200 lL of the vehicle formulation only
q.d. for 3 days. On day 20, hamsters were sacriﬁced and their intes-
tinal worm burdens were enumerated.3. Results
By probing the GenBank hookworm EST database using the
tBLASTn algorithm with a C. elegans GR amino acid sequence, it
was possible to obtain A. ceylanicum sequences that were assem-
bled into a complete protein open reading frame (ORF). From the
22 ESTs identiﬁed, AceGR was predicted to be 457 aa long, and
nucleotide sequence identity with the parasitic nematode Ascaris
suum GR, the parasitic nematode Brugia malayi GR, and human
GR was evaluated (Table 1). The putative AceGR sequence exhib-
ited amino acid residue conservation with other GR proteins,
including 68% identity with GR from the parasitic nematodes A.
suum and B. malayi.
Expression of rAceGR was veriﬁed using SDS–PAGE and immu-
noblot analyses. Coomassie-stained elution fractions of the col-
umn-puriﬁed recombinant protein indicated uniform elution of
the protein from the column with the expected molecular weight
of 53.09 kDa. Protein purity was high, as no other visible bands
were present on the stained gel, and this was conﬁrmed by immu-
noblot. To assess GR activity of the recombinant protein, a GR assay
that catalyzed the reduction of GSSG to GSH, which then reacts
with DTNB (Ellman’s reagent) to form NTB2, was used. The spe-
ciﬁc activity of the recombinant protein was found to be 0.66 U/
mg.
The kinetic constants of rAceGR with its substrates were deter-
mined by obtaining the initial velocities of reactions and graphing
these against varying concentrations of substrate. The concentra-
tion of each substrate under analysis was varied in turn while all
other reagent concentrations were held constant. Higher Km and
Vmax values were observed for rAceGR activity in the presence of
GSSG than for rAceGR with NADPH (Table 2). Enzyme activity in
the presence of DMSO was examined to determine if the introduc-
tion of the DMSO compound diluents to the reaction mixture
would contribute to the inhibitory effects of the furoxan analog
compounds. The presence of 0.5% DMSO had an observable effect
upon reaction rate, with DMSO concentrations above 2.5% inhibit-
ing the reaction entirely. This indicates that rAceGR enzyme activ-
ity is highly sensitive to DMSO.
An initial screening of furoxan and its analog compounds was
conducted against rAceGR to determine which of the 41 com-
pounds (Supplementary data) should be investigated further. All
compounds were used at a ﬁnal concentration of 50 lM, and a con-
trol reaction using an equivalent volume of DMSO was concur-
rently tested to control for the inhibitory effects of DMSO (as
established previously). The parent compound, furoxan, did not in-
hibit rAceGR to a signiﬁcant extent, requiring well over the upper
threshold concentration of 50 lM to exert an effect on enzyme
activity. Ten of the initial 41 compounds were found to effectively
inhibit rAceGR at this concentration: 2, 4, 5, 6, 9, 17, 20, 29, 36, and
39 (Table 3). Dilution series, in which the inhibitor was present at
Table 1
A. ceylanicum glutathione reductase identiﬁcation and cloning.
Description of cDNA #ESTs Predicted size BLASTx homology to A. ceylanicum ORF % ID
A. ceylanicum GR 22 457 aa C. elegans GR 76
B. malayi GR 68
H. sapiens GR 56
Primer sequences
A. ceylanicum GR AceGR for0: ACAAGCCAGTTGGACGATCTG
AceGR rev0: ACGTTTCCAGTTCACCGGAC
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each of these 10 inhibitors, and IC50 values were obtained for com-
pounds 2, 9, and 20. All IC50 values were below 3 lM, indicating
that the corresponding compounds were potent inhibitors of the
enzyme. The remaining compounds in Table 3 (5, 17, 29, 36, and
39) were only found to inhibit the enzyme at a concentration of
50 lM. Dilution curves for these compounds did not result in de-
ﬁned dose–response curves and no IC50 could be calculated given
the inhibitor concentration range used.
Next, we investigated whether a relationship existed between a
given compound’s ability to inhibit rAceGR and its potency in an
ex vivo worm killing assay. Compounds were evaluated based on
their ability to cause adult A. ceylanicum worm death at 100 lM
within 120 h. In all, 15 compounds effected 50% or greater worm
death (Table 4). Compounds 7, 39, 9, and 26 were at least 90%
effective at reducing worm survival, while compounds 12, 6, 30,
21, and 1 were at least 70% effective. Parasite survival was reduced
by at least 50% for compounds 22, 23, 24, 31, 4, and 25. Although all
inhibitors in Table 3 either moderately or strongly inhibited rAce-
GR, only compounds 9 and 39 were found to both inhibit rAceGR at
concentrations of 50 lM or less and result in signiﬁcant (>50%)
worm killing in the ex vivo worm killing assays. Compound 9
was found to be the sole effective compound that both inhibited
rAceGR activity and resulted in ex vivo worm killing.
The inhibitory effects of several of these furoxan analog com-
pounds have been analyzed with human GR (hGR) and rat thiore-
doxin reductase (rTrxR) (Rai et al., 2009). Of the seven inhibitors
tested against hGR, six—26, 12, 30, 21, 1, and 22—possessed IC50
values above the threshold 50 lM. These same six compounds also
possessed IC50 values above 50 lM when tested against rAceGR.
Compound 24 most strongly inhibited hGR, having an IC50 value
of 45.3 lM. Similarly, rTrxR was most strongly inhibited by com-
pound 24, with an IC50 value of <12.5 lM; however, the IC50 of
rAceGR for this compound was >50 lM. IC50 values for the effective
inhibitors of rAceGR have yet to be obtained with hGR and rTrxR.
We next tested the ability of furoxan to positively inﬂuence ani-
mal weight, blood hemoglobin levels, and intestinal worm burdens
as compared to infected vehicle-treated controls. Oral dosing with
furoxan at 50 mg/kg formulated in 10% DMSO: 40% propylene car-
bonate: 50% saline signiﬁcantly improved weight gain (Fig. 1A;Table 2
Comparison of kinetic properties of parasitic nematode glutathione reductase
enzymes.
Kinetic constants Enzyme source
A. ceylanicum A. suuma Onchocerca volvulusb
Km, NADPH (lM) 7.53 ± 1.38 6.4 10.9 ± 2.4
Km, GSSG (lM) 74.9 ± 15.9 94 130.7 ± 13.0
Vmax 0.0035 ± 0.006 c c
a Komuniecki, R., Bruchhaus, I., Ilg, T., Wilson, K., Zhang, Y., Fairlamb, A. H. (1992).
Molecular and 51, 331–333.
b Müller, S., Gilberger, T.-wolf, Fairlamb, A. H., Walter, R. D. (1997). J Biochem 325,
645–651.
c Not available.P < 0.05 and P < 0.001, 16 and 20 DPI, respectively) and brought
about a 52% reduction in intestinal worm burdens (Fig. 1B;
P < 0.05, 20 DPI, 37.5 worms per animal vs. 18 worms per animal).
Treatment with ABZ also signiﬁcantly improved weight gain
(P < 0.05 and P < 0.001, 16 and 20 DPI) and eliminated intestinal
worm burdens compared to infected control animals (Fig. 1B;
P < 0.01, 20 DPI).4. Discussion
With the widespread and continued burden of hookworm dis-
ease, the discovery of novel anthelminthic drugs and a correspond-
ing understanding of their mechanisms of action play a
fundamental role in the development of effective and robust ther-
apies. As stated previously, furoxan and its analogs target Schisto-
soma mansoni TGR and cause parasite death in vitro as well as
in vivo (Alger and Williams, 2002; Rai et al., 2009). The goal of this
research was two-fold: to identify oxadiazole 2-oxides that are
lethal to hookworms and to determine whether the antioxidant
enzyme AceGR serves as the biological target. Using prototypical
GR sequences, A. ceylanicum cDNA sequences were identiﬁed that
shared extensive sequence homology with GR proteins from other
taxa. The A. ceylanicum GR sequence described in this report con-
tains the conserved active site sequence of -Cys44-Val-Asn-Val-
Gly-Cys49-that is typical of functional GR, TrxR, and TGR proteins
(Holmgren and Bjornstedt, 1995; Kanzonk et al., 2002; Kuntz
et al., 2007). It is of note that the speciﬁc C-terminal redox center
of Gly-Cys-Sec-Gly (where Sec is selenocysteine) that is present
in Sec-containing TrxR and TGR proteins is not present in the hook-
worm GR sequence (Lee et al., 2000; Sandalova et al., 2001; Salinas
et al., 2004). Additionally, the amino acid sequence of AceGR exhib-
ited highest percent amino acid identity with GR sequences from A.
suum, B. malayi, and Loa loa (68%, 68%, and 67%, respectively). In
contrast, amino acid percent identity with the TrxR proteins of
these same organisms was markedly lower, at 33%, 36%, and 35%,
respectively. These data suggest that AceGR does not possess the
capacity for thioredoxin reductase activity and is not a multifunc-
tional redox protein; rather, it serves uniquely as a GR enzyme.Table 3
Oxadiazole 2-oxide compounds displaying 50% or greater rAceGR inhibitory activity.
ID# IC50 (lM) Ex vivo hookworm killing
rAceGR hGR rTrxR -Survival at 5 days (%)
2 0.11 35.2 <12.5 90
9 1.73 a a 10
20 2.1 a a 100
4 >50 a a 45
5 >50 >50 >400 95
6 >50 a a 20
17 >50 >50 250 58
29 >50 >50 150 80
36 >50 a a 100
39 >50 a a 8
a No data available.
Table 4
Oxadiazole 2-oxide compounds displaying 50% or greater ex vivo worm killing
activity.
ID# Ex vivo Hookworm Killing IC50 (lM)
-Survival at X days rAceGR
7 0% at 5 days >50
39 8% at 5 days >50
9 10% at 5 days 1.73
26 10% at 4 days >50
12 13% at 3 days >50
6 20% at 5 days >50
30 20% at 5 days >50
21 29% at 3 days >50
1 30% at 4 days >50
22 35% at 5 days >50
23 35% at 5 days >50
24 35% at 4 days >50
31 43% at 3 days >50
4 45% at 5 days >50
25 50% at 3 days >50
Fig. 1. Oral administration of furoxan improves intestinal worm burdens of A. ceylanicum and animal weight gain. Groups of Syrian hamsters (n = 4) were infected with 75
third stage A. ceylanicum larvae and followed for 20 days to monitor blood hemoglobin levels and weight gain. On days 12–14 post-infection hamsters were treated orally
with furoxan (50 mg/kg) or vehicle alone. At 20 days post infection, all hamsters were sacriﬁced and intestinal worm burdens enumerated. Compared to infected vehicle
controls, hamsters treated with furoxan had improved weight gain (P < 0.05 and P < 0.001, 16 and 20 DPI, respectively; Panel A) and signiﬁcantly lower worm burdens
(P < 0.05; Panel B).
R.S. Treger et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 171–177 175This further suggests that the GSH and Trx pathways in A. ceylani-
cum are structurally and functionally distinct, with each possessing
a unique set of redox enzymes. While these results by no means
conﬁrm the absence of such a multifunctional TGR protein as is
present in the cestodes and trematodes, it is of note that conven-
tional GR proteins are absent from these same platyhelminths
(Salinas et al., 2004; Prast-Nielsen et al., 2011). This discovery of
a distinct hookworm GR protein therefore strongly supports the
hypothesis that separate Trx and GSH antioxidant pathways exist
in hookworms and points to either or both of these pathways as
potential targets of the furoxan compounds.
While high sequence identity was observed between hook-
worm GR and the GRs of other nematodes, a lower percent amino
acid sequence identity of 57% was identiﬁed between AceGR and
human GR. Given this fact, it stands to reason that unique local
and/or global structural conformations exist that may differentiate
the hookworm GR homolog as a drug target and ensure the neces-
sary speciﬁcity in terms of chemotherapeutic development.
A high-throughput screen of over 70,000 small molecules iden-
tiﬁed furoxan, the parent compound in this group of oxadiazole 2-
oxides, as a potent inhibitor of S. mansoni TGR (Lea et al., 2008).
Based upon these results, we hypothesized that furoxan would
be an effective inhibitor of AceGR. However, furoxan did not signif-
icantly reduce the initial rate of reaction, indicating that this com-
pound does not substantially inhibit rAceGR. Similarly, a
preliminary screening of 41 furoxan analogs revealed that only
10 were able to inhibit enzyme activity by at least 50%. These ﬁnd-
ings indicate that independent of their capacity to inhibit hook-
worm survival ex vivo, over three-quarters of these oxadiazole 2-
oxides do not speciﬁcally inhibit rAceGR enzyme activity in vitro.
Among the analogs that were effective inhibitors, only compounds
2, 9, and 20 possessed IC50 values below 50 lM. It is of note that
although very few of the tested furoxan analogs promoted strong
inhibition at physiologically relevant concentrations, those select
compounds that did, did so at relatively low inhibitor concentra-
tions (all IC50 values below 3 lM).
To correlate hookworm killing with the inhibition of AceGR by
the oxadiazole 2-oxides, it was necessary to establish a relation-
ship between in vitro rAceGR inhibition and ex vivo parasite mor-
tality. Treatment with 15 of the furoxan analogs resulted in at
least 50% parasite death, and parasite survival was <30% for com-
pounds 12, 6, 30, 21, and 1. Compounds 7, 39, 9, and 26 resulted
in a parasite survival rate <10%. Yet, despite the ability of roughlyone-third of these compounds to increase worm mortality, little
overlap existed between AceGR inhibition and worm toxicity.
While compounds 9 and 39 resulted in both marked enzyme inhi-
bition in the preliminary screen and signiﬁcant worm mortality
ex vivo, 9 was the only species of this pair to also exhibit an IC50
value below 50 lM. This was therefore the only compound tested
that satisfactorily established a relationship between the two
factors.
The above results allow for several important conclusions to be
drawn regarding the nature of AceGR and its interaction with oxa-
diazole 2-oxides. First, this class of compounds does not generally
appear to inhibit AceGR activity in vitro, as only three compounds
signiﬁcantly inhibited AceGR. Rather, most inhibitors resulted in
only partial inhibition of activity, even at this upper threshold con-
centration. It therefore appears likely that the mechanism by
which furoxan and its analogs kill A. ceylanicum involves a target
other than AceGR.
The above result does not appear to support the hypothesis that
AceGR serves as the primary target for the action of these mole-
cules. Only a small number of oxadiazoles inhibited AceGR activity.
This partial inhibitory activity suggests that oxadiazole 2-oxide-
dependent inhibition of AceGR contributes to the overall observed
hookworm mortality in the ex vivo and in vivo experiments. In or-
176 R.S. Treger et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 171–177der to identify the major target of furoxan in hookworms, it will be
necessary to investigate the inhibition proﬁles of the Trx pathway
in the presence of the furoxan and analog compounds.
Second, the enzyme inhibition and hookworm killing data to-
gether suggest that among the compounds tested, potent enzyme
inhibitors are not (with the exception of 9) toxic to the adult hook-
worm ex vivo. A ﬁrst interpretation of this data is that furoxan and
its analogs decrease worm survival via a mechanism that does not
directly involve the inhibition of GR. This would account for both
the broader spectrum of ex vivo mortality and the low level of en-
zyme inhibition. However, the discovery by Rai et al. (2009) that
nitric-oxide (NO) donation plays a key role in ex vivo oxadiazole
2-oxide toxicity allows for a more nuanced interpretation. From
an examination of the ability of oxadiazole 2-oxide compounds
to donate NO in the presence of S. mansoni TGR, it was concluded
that NO donation by the compounds was necessary in order for
parasite death to occur (2009). It is therefore possible that AceGR
does, in fact, serve as a target for the furoxan compounds, but that
this same relationship exists with regard to AceGR inhibition, NO
donation, and parasite mortality. Potent AceGR inhibitors such as
2 and 20 that do not signiﬁcantly result in worm death may simply
fail to donate any or enough of the requisite NO. Moreover, it has
been observed that the addition of NO scavengers such as 2-(4-car-
boxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (car-
boxy-PTIO) to the reaction medium can partially counteract the
toxic effects of oxadiazole 2-oxide compounds (Alger andWilliams,
2002; Sayed et al., 2008). The presence of such a molecule (or mol-
ecules) or enzymatic activity in high enough concentrations in the
ex vivo assay would abrogate most or all of the toxic effects that the
furoxan analogs may have otherwise induced. It is possible that
endogenous NO scavengers or other similar compounds present
in the adult worm are able to ameliorate the effects of the NO re-
lease and thereby prevent worm death. While the oxadiazole 2-
oxide compounds tested in this research do not exhibit a consistent
relationship between AceGR inhibition and worm toxicity, examin-
ing the capacity of these compounds to donate NO in the presence
of AceGR may prove revealing. From this it would be possible to
determine if the discrepancy between potent enzyme inhibition
and potent toxicity was the result of poor NO donation or a mech-
anism that does not target AceGR. It is also possible that there is a
low bioavailability of these potent AceGR enzyme inhibitors within
the worms during ex vivo culture and that these compounds do not
have access to native AceGR. Further studies will be conducted to
determine if AceGR activity is inhibited in worms that have been
treated with these inhibitor compounds. Lastly, inhibition of the
GSH system does not preclude continued activity in the Trx sys-
tem. Ex vivoworm death may therefore be prevented or modulated
by the ability of the Trx pathway to independently mediate the
ROS present in the in vitro environment. It is possible that ex vivo
nematicidal activity will better correlate to the inhibition of both
the GSH and Trx pathways, rather than that of the GSH system
alone.
Despite public health initiatives to reduce its many risk factors,
hookworm disease remains prevalent across the globe. While an
effective drug therapy exists in the form of the benzimidazoles,
other alternative chemotherapies are not currently available, mak-
ing the treatment of hookworm infection reliant upon the contin-
ued susceptibility of the parasite to these drugs. Resistance to
anthelmintic drugs (e.g. benzamidazoles, ivermectin, and levam-
isole) has developed in veterinary nematodes and has been exten-
sively documented (Prichard, 1994; von Samson-Himmelstjerna
and Blackhall, 2005; Craig, 2006; Keiser and Utzinger, 2010). While
these same levels of resistance have yet been reported in humans
isolates, low cure rates associated with benzimidazoles in studies
of human hookworm infection continue to increase and anthel-
minthic resistance cannot be ruled out as a primary cause (DeClercq et al., 1997; Keiser and Utzinger, 2008; Humphries et al.,
2011). Therefore, it is imperative to continue efforts to identify no-
vel chemotherapeutic lead compounds for the treatment of hook-
worm disease and other soil-transmitted nematodes. Studies
such as these aimed at characterizing parasite proteins involved
in bloodmeal metabolism and detoxiﬁcation of ROS will likely pro-
duce numerous viable targets for the creation of new
anthelminthics.
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